Breaking Finance News

A statement released earlier today by Morgan Stanley about Cytokinetics Inc (NDAQ:CYTK) bumps down the target price to $17.00

Displaying a price of $8.00, Cytokinetics Inc (NDAQ:CYTK) traded -1.01% lower on the day. The last stock price is down 4.99% from the 200-day moving average, compared to the S&P 500 which has increased 0.01% over the same time period. CYTK has recorded a 50-day moving average of $14.77 and a 200-day moving average of $13.95. 402,408 shares of the stock were exchanged, down from an average trading volume of 450,903

Stating a potential upside of 1.12%, Morgan Stanley lowered the target price of Cytokinetics Inc (NDAQ:CYTK) to $17.00

On 11/21/2017, H.C. Wainwright released a statement on Cytokinetics Inc (NDAQ:CYTK) bumped down the target price from $26.00 to $17.00 that suggested an upside of 1.12%.

See Chart Below

Cytokinetics Inc (NDAQ:CYTK)

Cytokinetics Inc has a 52 week low of $8.77 and a 52 week high of $17.20 CYTK’s total market value is presently $0.

A total of 6 brokerages have issued a ratings update on the company. 1 firm rating the stock a strong buy, 5 firms rating the stock a buy, 0 brokers rating the stock a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the stock a sell with a consensus target price of $19.17.

About Cytokinetics Inc (NDAQ:CYTK)

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.